rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GTCB los ?

27.049 Posts
Pagina: «« 1 ... 1158 1159 1160 1161 1162 ... 1353 »» | Laatste | Omlaag ↓
  1. [verwijderd] 23 februari 2006 12:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Analisten voor zo'n klein bedrijfje ? Laat me niet lachen, ze hebben in de states honderduizenden andere bedrijven te coveren. als ze boven de 5 of 10 dollar komen en een steady revenue hebben, dan misschien ja. Ik ken niet veel analisten die prijzen plakken op een puur research bedrijfje ook, veel te gevaarlijk.

    quote:

    Henk Snaph schreef:

    [quote=Tweeke]
    [quote=arend007]
    De berichttgeving hier is prima, maar heb wel 1 vraag. Waarom staat er geen nieuws op Nasdaq of Wallstreet of andere sites. Er is totaal geen nieuws te vinden met onderbouwing van GTCB.
    [/quote]
    Dat is niet vreemd. Alles wat je nu hoort IS geen nieuws, heeft allang eerder in persberichten en interviews gestaan.
    Voor het grote publiek is het nieuw ja.
    Je hoeft van GTCB niet te verwachten dat ze in een persbericht melden op welke zenders ze te zien zijn en hoe laat.

    [/quote]

    Wat mij echter wel bevreemd is dat er zich nog steeds geen analisten melden!

    Henks
  2. [verwijderd] 23 februari 2006 12:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik hoop alleen wel dat ze voorbeurs komen, maar waarschijnlijk niet. Dus kunnen ze natuurlijk nog ongelooflijk hard gaan shuffelen na opening. Dan kan je ze pas echt bang maken!!

    Groet,

    IM.
  3. [verwijderd] 23 februari 2006 13:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    PRVIEW schreef:

    nog 3 uurtjes en we weten meer !!!
    tik tak tik tak...gaat de tijd langzamer vandaag, of ligt dat aan mij.

    Ik begin nu toch bijna nerveus te worden. :-)
  5. [verwijderd] 23 februari 2006 13:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Elbee schreef:

    [quote=PRVIEW]
    nog 3 uurtjes en we weten meer !!!
    [/quote]

    tik tak tik tak...gaat de tijd langzamer vandaag, of ligt dat aan mij.

    Ik begin nu toch bijna nerveus te worden. :-)
    Geen enkele reden om nerveus te worden. Wij kunnen, net zomin GTCB trouwens, iets aan de uitslag veranderen. Tot en met gisteren zijn posities ingenomen op, naar ik hoop, rationele gronden. Vandaag moet pay day worden na al het intensieve werk.

    groet,

    Schouterman
  7. ludwig mack 23 februari 2006 13:35

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 11 apr 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    Schouterman schreef:

    [quote=Elbee]
    [quote=PRVIEW]
    nog 3 uurtjes en we weten meer !!!
    [/quote]

    tik tak tik tak...gaat de tijd langzamer vandaag, of ligt dat aan mij.

    Ik begin nu toch bijna nerveus te worden. :-)
    [/quote]

    Geen enkele reden om nerveus te worden. Wij kunnen, net zomin GTCB trouwens, iets aan de uitslag veranderen. Tot en met gisteren zijn posities ingenomen op, naar ik hoop, rationele gronden. Vandaag moet pay day worden na al het intensieve werk.

    groet,

    Schouterman
    ik hoop dat je genoeg cash hebt schouterman, want je wilde bij goedkeuring toch bijkopen :)
  9. ludwig mack 23 februari 2006 13:37

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 11 apr 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    gismo74 schreef:

    GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)
    Thursday February 23, 7:34 am ET
    zonder bron ....
  10. [verwijderd] 23 februari 2006 13:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)

    E-mail | Print | | Disable live quotes Last Update: 7:34 AM ET Feb 23, 2006

    FRAMINGHAM, Mass., Feb 23, 2006 (BUSINESS WIRE) -- GTC Biotherapeutics, Inc. (GTCB : gtc biotherapeutics inc com
    News , chart, profile, more
    Last: 2.25+0.05+2.27%

    7:00am 02/23/2006
    Add to portfolio
    Analyst
    Create alertInsider
    Discuss
    Financials
    Sponsored by:
    GTCB2.25, +0.05, +2.3%) announced today that it has been told that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) intends to issue a negative opinion on the market authorization application (MAA) for ATryn(R), GTC's recombinant form of human antithrombin. On the basis of recent conversations, GTC understands that the CHMP, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval. In addition, GTC understands that the CHMP has concerns about sufficient immunologic data and the lack of clinical data from ATryn(R) produced with an additional filtration step. GTC intends to take advantage of the appeal process to request a CHMP re-examination of GTC's submission.
    GTC's European development and commercialization partner, LEO Pharma A/S, has affirmed that they remain committed to their collaboration with GTC and will continue to pursue the primary goal of development of an acquired deficiency indication for Europe. Acquired deficiency indications represent the most significant market opportunity for the product. GTC and LEO entered into a collaborative development and commercialization agreement for ATryn(R) in Europe, Canada, and the Middle East in November 2005. GTC is also continuing a multinational study of ATryn(R) in hereditary antithrombin deficient patients in preparation for submission of a Biologics License Application (BLA) in the U.S. Enrollment is planned to be completed in 2006 and a BLA submitted in the first half of 2007.
    "Although we are very disappointed with the late-breaking concerns on the clinical data and the negative opinion, we are pleased by the commitment of LEO Pharma to continue working on further development of this important product in Europe in acquired antithrombin deficiency," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "In addition we remain committed to completing our submission for BLA approval in the US. The US remains a major long term opportunity for ATryn(R) in a range of hereditary and acquired deficiency indications. It is also important for our transgenic technology platform that the CHMP has not identified to us any significant outstanding issues related to the manufacturing and production control systems for ATryn(R)."
    Antithrombin is a protein in human plasma that has anticoagulant and anti-inflammatory properties. Patients that have a hereditary deficiency indication are prone to developing blood clots during high-risk procedures, such as surgery and childbirth. Providing supplemental antithrombin during these procedures may prevent the occurrence of DVT's and other thromboembolic events. Antithrombin supplementation therapy may also be useful in the treatment of patients who acquire temporary antithrombin deficiency during certain clinical situations such as burns, coronary artery bypass surgery, disseminated intravascular coagulation, sepsis, and bone marrow transplant.
    Conference Call Information
    GTC will discuss this opinion and the status of ATryn(R) in a web cast conference call at 9:00 a.m. (Eastern) today. The web cast may be heard through GTC's web site at www.gtc-bio.com. The dial-in number from inside the United States is 1-800-901-5231. The dial-in number from outside the United States is 1-617-786-2961. The participant passcode is 41916712.
    About GTC Biotherapeutics, Inc.
    GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. In addition to the ATryn(R) program, GTC is developing recombinant human alpha-1 antitrypsin, recombinant human albumin, a CD137 antibody as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.
    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding its expectations for the final CHMP opinion, the development of an acquired deficiency indication with LEO, the ongoing phase III study and preparation of a BLA, and GTC's request for a CHMP re-examination of the submission. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with regulatory approval and the actions of partners. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.
    SOURCE: GTC Biotherapeutics, Inc.
    GTC Biotherapeutics, Inc. Thomas E. Newberry, 508-370-5374 or Feinstein Kean Healthcare for GTC Biotherapeutics, Inc. Francesca DeVellis, 617-577-8110 Copyright Business Wire 2006 ********************************************************************** As of Sunday, 02-19-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 11-03-2005 for GTCB @ $1.71. (C) 2006 Comtex News Network, Inc. All rights reserved.


    E-mail | Print | | Disable live quotes 6:40AM 2/23/2006Stock futures search for catalyst after Wednesday rise
    5:58AM 2/23/2006Toll Brothers earnings rise 49%, top forecast
    5:51AM 2/23/2006Reuters shares tumble on outlook concerns
    5:09AM 2/23/2006Utilities spark European gains
    8:00PM 2/22/2006Government solicits bids on nuclear disaster drugs
    More newsSponsored Links
    Get listed hereBuy Stocks Online at Scottrade
    $7 stock trades at Scottrade. No account inactivity or maintenance fees. Open an account for $500. Apply today.
    www.scottrade.com

    Tomorrow's Hot Stock Pick
    Free reports, picks, and tips on potentially huge winners. Penny stocks, undervalued, and undiscovered situations. Unique ideas to make money now.
    www.RocketStockPicks.com

    15 Energy Stocks to Sell Now
    Natural gas prices top $20! Free report reveals the truth about this crisis and how you can profit. 15 big-name losers to avoid. The case for $100 oil. And more – all free.
    www.changewave.com
  12. positivo73 23 februari 2006 13:37

    • positivo73

      Lid sinds: 25 mrt 2004

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 370

      Gegeven: 163

    •    Aantal posts: 6.036

    quote:

    gismo74 schreef:

    GTC Biotherapeutics Expects CHMP to Issue Negative Opinion on ATryn(R)
    Thursday February 23, 7:34 am ET
    ???
  20. [verwijderd] 23 februari 2006 13:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zo ben ik blij dat ik gisteren de gok heb gemaakt te verkopen, het is ook altijd wat bij gtcb. Je wordt er moe van. Ik geloof er niet meer in.
27.049 Posts
Pagina: «« 1 ... 1158 1159 1160 1161 1162 ... 1353 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.160
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.502
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.931
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.892
Aedifica 3 927
Aegon 3.258 323.212
AFC Ajax 538 7.093
Affimed NV 2 6.306
ageas 5.844 109.909
Agfa-Gevaert 14 2.074
Ahold 3.538 74.361
Air France - KLM 1.025 35.329
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.068
Alfen 16 25.502
Allfunds Group 4 1.525
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.244
AMG 972 134.752
AMS 3 73
Amsterdam Commodities 305 6.754
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.106
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.093
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.379
Aroundtown SA 1 221
Arrowhead Research 5 9.758
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.697
ASML 1.767 112.199
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 523
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.343
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.463